Clinical trial · Observational

Studying DNA in Samples From Younger Patients With Down Syndrome and Acute Myeloid Leukemia Treated on COG-AAML0431 Clinical Trial

Whole Exon Sequencing of Down Syndrome Acute Myeloid Leukemia

NCT01507441CI-TRIAL-00022260completedClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

RATIONALE: Studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research trial studies DNA samples from patients with Down syndrome and acute myeloid leukemia treated on COG-AAML0431 clinical trial.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Leukemia	Leukemia	ONTOLOGY_EXACT	0.90

Interventions

Interventions (5)

Intervention	Type	Mapped drug	Match
gene mapping	Genetic	—	UNRESOLVED
laboratory biomarker analysis	Other	—	UNRESOLVED
microarray analysis	Genetic	—	UNRESOLVED
mutation analysis	Genetic	—	UNRESOLVED
nucleic acid sequencing	Genetic	—	UNRESOLVED

Design

Arms and outcomes

Arms (0)

[]

Primary outcomes (1)

measure
Identification of unique mutations through whole-genome sequencing

Eligibility

Eligibility (as posted)

Sex: All
Maximum age: 3 Years

Show eligibility criteria text

DISEASE CHARACTERISTICS:

* Down syndrome children diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS)
* Clinical samples from patients enrolled on the Children's Oncology Group (COG) AAML0431 phase III clinical trial, and from the Children's Hospital of Michigan Cell Bank

  * Diagnostic blast samples and matched remission samples

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* Not specified

References

Publications (0)

Data not yet available

No reference posted for this study.